CLRB · XBRL financial data
Cellectar Biosciences financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (CLRB's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | †Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Research and development | 10,141 | 17,586 | 19,220 | 27,266 | 26,136 | 11,499 |
| General and administrative | 5,150 | 6,545 | 9,594 | 11,694 | 25,641 | 11,481 |
| Operating income (loss) | (15,290) | (24,131) | (28,814) | (38,961) | (51,778) | (22,980) |
| Income tax expense (benefit) | — | — | (60) | (60) | 66 | — |
| Net income (loss) | (15,094) | (24,122) | (28,601) | (42,771) | (44,581) | (21,791) |
| Earnings per share, basic‡ USD per share | (2,303.03) | (1,303.03) | (122.73) | (106.06) | (36.97) | (8.35) |
| Earnings per share, diluted‡ USD per share | (5,575.76) | (2,303.03) | (122.73) | (106.06) | (42.42) | (8.35) |
| Weighted average shares, basic‡ thousands of shares | 7 | 18 | 233 | 403 | 1,209 | 2,608 |
| Weighted average shares, diluted‡ thousands of shares | 7 | 18 | 233 | 403 | 1,226 | 2,608 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (June 2022); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (June 2022); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-30.3030303030303 stock split (June 2025); filings made before it reported them unadjusted.
- † Share count changed about 16x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (CLRB's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | †Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 57,165 | 35,704 | 19,866 | 9,565 | 23,289 | 13,196 |
| Prepaid and other current assets | 774 | 867 | 663 | 888 | 962 | 842 |
| Total current assets | 57,940 | 36,571 | 20,530 | 10,453 | 24,250 | 14,038 |
| Property and equipment, net | 356 | 344 | 419 | 1,090 | 757 | 549 |
| Right-of-use asset | 282 | 205 | 560 | 502 | 437 | 361 |
| Total assets | 58,659 | 37,202 | 21,590 | 12,076 | 25,474 | 14,978 |
| Accounts payable | 1,429 | 1,415 | 2,558 | 5,620 | 4,105 | 1,441 |
| Total current liabilities | 3,563 | 3,990 | 5,529 | 25,359 | 9,388 | 4,750 |
| Lease liability, non-current | 302 | 166 | 553 | 494 | 410 | 309 |
| Total liabilities | 3,865 | 4,157 | 6,082 | 25,853 | 9,797 | 5,059 |
| Accumulated deficit | (126,775) | (150,898) | (179,499) | (202,761) | (247,342) | (269,134) |
| Total stockholders' equity | 54,795 | 33,045 | 15,508 | (15,159) | 14,295 | 8,537 |
| Total liabilities and equity | 58,659 | 37,202 | 21,590 | 12,076 | 25,474 | 14,978 |
| Common shares outstanding (cover page)‡ thousands of shares | 17 | 20 | 321 | 1,065 | 1,521 | 4,240 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (June 2022); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (June 2022); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-30.3030303030303 stock split (June 2025); filings made before it reported them unadjusted.
- † Share count changed about 16x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (CLRB's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | †Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (15,094) | (24,122) | (28,601) | (42,771) | (44,581) | (21,791) |
| Stock-based compensation | 468 | 1,124 | 1,453 | 2,410 | 4,273 | 2,264 |
| Depreciation and amortization | 141 | 150 | 148 | 192 | 292 | 214 |
| Net cash from operating activities | (13,933) | (22,569) | (25,222) | (32,377) | (47,583) | (23,118) |
| Purchases of property and equipment | 62 | 141 | 226 | 864 | 104 | 6 |
| Net cash from investing activities | (62) | (141) | (226) | (864) | (104) | (6) |
| Proceeds from issuing common stock | 59,719 | 35 | 9,611 | — | — | — |
| Proceeds from long-term debt | 184 | — | — | — | — | — |
| Net cash from financing activities | 60,546 | 1,249 | 9,611 | 22,940 | 61,411 | 13,032 |
| Net change in cash | 46,551 | (21,461) | (15,838) | (10,301) | 13,724 | (10,093) |
- † Share count changed about 16x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Cellectar Biosciences | 33,994 | not reported | (6,010)* | 9.5M | 5.7 quarters | 10-QJun 30, 2026 |
| Synergy CHC | 292 | 5,493 | (2,045) | 14.9M | 0.1 quarters | 10-QMar 31, 2026 |
| Earth Science Tech | 631 | 9,026 | 707 | 287.6M | — | 10-QJun 30, 2026 |
| Cypherpunk Technologies | 7,624 | not reported | (2,692)* | 107.8M | 2.8 quarters | 10-QJun 30, 2026 |
| GeoVax Labs | 3,143 | not reported | (3,658)* | 7.4M | 0.9 quarters | 10-QJun 30, 2026 |
| Edesa Biotech | 10,300 | not reported | (3,083)* | 9.6M | 3.3 quarters | 10-QJun 30, 2026 |
| Cocrystal Pharma | 2,169 | 105 | (2,516)* | 19.3M | 0.9 quarters | 10-QJun 30, 2026 |
| Citius Pharmaceuticals | 17,008 | 1,494 | (8,678)* | 27.5M | 2.0 quarters | 10-QJun 30, 2026 |
| Phio Pharmaceuticals | 12,996 | not reported | (4,035)* | 11.6M | 3.2 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.